25 Apr 2018

UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook

Read More
19 Apr 2018

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

Read More
4 Apr 2018

UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spin-off

Read More
2 Apr 2018

New publication on Cimzia® (certolizumab pegol) shows psoriatic arthritis patients achieved robust treatment targets and sustained improvements across multiple disease domains

Read More
30 Mar 2018

Acquisition of own shares

Read More
30 Mar 2018

Transparency notification The Capital Group Companies Inc.

Read More
29 Mar 2018

UCB Announces Filing Acceptance with the China Food and Drug Administration for CIMZIA® (certolizumab pegol) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

Read More
22 Mar 2018

CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

Read More
22 Feb 2018

UCB Full Year Report 2017: UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

Read More
16 Feb 2018

UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)

Read More
Subscribe to